10.3.2022 17:20:45 CET | Demant A/S |
Forløb af generalforsamling
Selskabsmeddelelse nr. 2022-07
10. marts 2022
Beslutninger på den ordinære generalforsamling
Demant A/S har i dag afholdt ordinær generalforsamling som et hybridmøde, der dels blev afholdt fysisk på selskabets adresse, og dels virtuelt.
I sin tale på generalforsamlingen redegjorde bestyrelsens formand, Niels B. Christiansen, for koncernens udvikling i 2021. Beretningen er tilgængelig på www.demant.com. I sin tale sagde formanden blandt andet:
“I starten af 2021 havde vi høje forventninger til markedsudviklingen for året, og vi er stolte over, at forventningerne holdt stik – og endda mere til. Alt i alt blev 2021 et fantastisk år for Demant, hvor vi leverede høj organisk vækst, og vores kernesegment, Hearing Healthcare, leverede en vækstrate, som lå over markedsvækstraten. Koncernen nåede en rekordhøj omsætning på mere end DKK 18 mia. og det bedste resultat af primær drift (EBIT) nogensinde på over DKK 3,4 mia.
Såvel i 2022 som i årene fremover forventer vi at se vækst og at øge vores markedsandele yderligere. Men dette kan kun ske ved hjælp af vores engagerede medarbejdere og deres dedikerede indsats, når det handler om at sikre høj kvalitet og yde deres bedste for at servicere vores kunder.”
Alle bestyrelsens forslag blev vedtaget af generalforsamlingen. Dette medførte blandt andet følgende beslutninger:
At selskabets årsrapport for 2021 blev godkendt, og at hele årets overskud, DKK 2.015 mio., overføres til selskabets reserver.
At vederlagsrapporten for 2021 blev godkendt.
At bestyrelseshonoraret forbliver det samme som i 2021.
At Niels B. Christiansen, Niels Jacobsen, Anja Madsen, Sisse Fjelsted Rasmussen og Kristian Villumsen blev genvalgt som bestyrelsesmedlemmer.
At selskabets revisionsfirma, Deloitte Statsautoriseret Revisionspartnerselskab, blev udskiftet med PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC) i overensstemmelse med lovkrav om rotation af revisionspartner og -selskab og med revisionsudvalgets indstilling.
At selskabets aktiekapital nedsættes med nominelt DKK 1.949.819,60 svarende til selskabets beholdning af egne aktier pr. 27. januar 2022. Beholdningen af egne aktier er erhvervet som led i selskabets aktietilbagekøb i 2021. Som konsekvens af kapitalnedsættelsen ændres vedtægternes pkt. 4.1 senest fire uger efter udløbet af fristen for kreditorers anmeldelse af krav, således at det herefter af pkt. 4.1 vil fremgå, at selskabets aktiekapital udgør DKK 46.075.747,00.
At bestyrelsen blev bemyndiget til indtil næste ordinære generalforsamling at lade selskabet tilbagekøbe aktier med en pålydende værdi af indtil 10 % af aktiekapitalen.
At den opdaterede vederlagspolitik, som blandt andet medfører ændring af vederlagsstrukturen for direktionen, blev godkendt.
Efter generalforsamlingen konstituerede bestyrelsen sig med Niels B. Christiansen som formand og Niels Jacobsen som næstformand.
Efter generalforsamlingen og godkendelsen af vederlagspolitikken besluttede bestyrelsen derudover at introducere et aktiebaseret program for direktionen som beskrevet i vederlagspolitikken.
I henhold til paragraf 3.8.1 i Nasdaqs Nordic Main Market Rulebook for Issuers of Shares, skal Demant hermed give følgende oplysninger:
Beskrivelse af programmet
Et langsigtet incitamentsprogram i form af Restricted Stock Units (RSU’er), som efter optjening konverteres 1:1 til aktier i selskabet.
I begyndelsen af en etårig performance-periode tildeles det maksimale antal RSU’er, der vil være optjent i slutningen af den treårige optjeningsperiode.
Ved udgangen af performance-perioden justeres antallet af RSU’er baseret på en vurdering af niveauet for opfyldelse af performance-kriterierne.
Værdien af RSU’erne kan ikke være mindre end 25 % af det pågældende direktionsmedlems årlige faste løn og kan ikke overstige 75 % af direktionsmedlemmets årlige faste løn.
Der henvises til selskabets vederlagspolitik for en mere detaljeret beskrivelse af programmet.
Performance-kriterier
Performance-kriterierne er nøje afstemt efter Demants strategi og vil typisk være knyttet til opfyldelse af finansielle og forretningsmæssige mål og til mål for bæredygtighed.
Personkreds omfattet af programmet
Direktionen pr. 1. april 2022
Optjeningsperiode
2022-2025, dvs. tre år
Performance-periode
2022, dvs. et år (det første år af optjeningsperioden)
Aktiekurs
DKK 271,70, dvs. gennemsnittet af kurserne noteret på Nasdaq i København de første fem handelsdage efter offentliggørelse af Demants årsrapport for 2021.
Samlet antal tildelte RSU’er
77.220
Programmets teoretiske markedsværdi
DKK 20.980.647 baseret på den aktiekurs, der anvendes til beregning af tildelingen. Beløbet repræsenterer den maksimale udbetaling, som justeres i forhold til performance-kriterierne.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Relations
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2022-07 Beslutninger på den ordinære generalforsamling.pdf
10.3.2022 17:20:45 CET | Demant A/S |
Decisions of general meeting
Company announcement no 2022-07
10 March 2022
Decisions of annual general meeting
Today, Demant A/S held its annual general meeting as a hybrid meeting, which took place both as a physical meeting at the company’s headquarters and as a virtual meeting.
In his address, the Chairman of the Board, Niels B. Christiansen, gave an account of the Group’s development in 2021. The report is available on www.demant.com. He said among other things:
“At the beginning of 2021, we had high hopes for the year’s market development, and we are proud to say that not only did we meet our expectations, but we also exceeded them. All in all, 2021 was a fantastic year for Demant where we delivered high organic growth, and our core segment, Hearing Healthcare, delivered a growth rate above the market growth rate. The Group generated record-high revenue of more than DKK 18 billion and the best operating profit (EBIT) ever of more than DKK 3.4 billion.
Both in 2022 and in the years to come, we expect to see growth and to gain further market shares. However, this is only doable through the dedicated efforts of our engaged employees when it comes to ensuring high quality and doing their utmost to provide excellent service to our customers.”
All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:
The company’s Annual Report 2021 was approved, and the year’s profit, DKK 2,015 million, will be transferred to the company’s reserves.
The Remuneration Report for 2021 was approved.
The Director’s fee remains the same as in 2021.
Niels B. Christiansen, Niels Jacobsen, Anja Madsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected members of the Board of Directors.
The company’s auditors, Deloitte Statsautoriseret Revisionspartnerselskab, were replaced by PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC) in compliance with legal requirements in respect of rotation of auditor and accounting firm and with the proposal put forward by the company’s audit committee.
The company’s share capital will be reduced by nominally DKK 1,949,819.60, corresponding to the company’s holding of treasury shares at 27 January 2022. The company’s holding of treasury shares was acquired during 2021 as part of the company’s share buy-back scheme. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 46,075,747.00.
Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.
The revised Remuneration Policy, which among other changes implies a change in the remuneration structure for the Executive Board, was approved.
After the general meeting, the Board of Directors elected Niels B. Christiansen Chairman and Niels Jacobsen Deputy Chairman of the Board.
Additionally, after the general meeting and following the approval of the Remuneration Policy, the Board of Directors decided to introduce a share-based programme for the Executive Board as part of their remuneration package as described in the Remuneration Policy.
Rf. Rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, the following information is hereby provided about the share-based programme:
Description of the programme
A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting.
At the beginning of a one-year performance period, the maximum number of RSUs that will vest at the end of a three-year vesting period is granted.
At the end of the performance period, the number of RSUs will be adjusted based on an assessment of the level of achievement of the performance criteria.
The value of the RSUs cannot be less than 25% of the annual fixed base salary of the Executive Board member in question, and the value cannot be more than 75% of the annual fixed base salary of the Executive Board member.
Please refer to the Remuneration Policy for a more detailed description of the programme.
Performance criteria
Performance criteria are closely aligned with Demant’s strategy and will typically be linked to financial, business and sustainability targets.
Group of persons covered by the programme
Executive Board as of 1 April 2022
Vesting period
2022-2025, i.e. three years
Performance period
2022, i.e. one year (the first year of the vesting period)
Share price used for grant calculation
DKK 271.70, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2021.
Total number of RSUs granted
77,220
The theoretical market value of the programme
DKK 20,980,647 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Relations
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2022-07 Decisions of annual general meeting.pdf
